Warby Parker, Inc. (WRBY)
NYSEHealth CareSpecialty RetailSnapshot 2026-11-04
$21.29-2.96%
Close 2026-11-04 · 1-day change
NYSEHealth CareSpecialty RetailSnapshot 2026-11-04
Research Workspace
Put WRBY beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Supplies is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve 10% to 12% revenue growth in 2026: Revenue growth: 9.81%.
View ThesisRevenue growth is slowing — up about 11% over the past year and decelerating.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 57% growth a year, above the roughly 21% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 33% in its worst 12-month stretch.
View RiskRecent financial performance is strong. Its last earnings result was a miss. Peer multiples imply a price about 83% below where it trades (it looks expensive on this basis). Risk is elevated. This read is provisional.
Trailing returns as of 2026-11-04. WRBY is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 13 analysts currently covering WRBY (as of Nov 2026).
Based on 3 Wall Street analysts offering 12-month price targets for WRBY in the last 4 months.
Continue this research
Compare WRBY with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| WRBY Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Supplies — fair value, gap to price, and forward P/E.
Compare the value case
Put WRBY next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Launch Intelligent Eyewear product line
Q3 results and smart glasses launch drive positive stock reaction.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $21.29
The last 12 months of price, then the range of analyst 12-month targets from today’s $21.29.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Achieve 10% to 12% revenue growth in 2026
EPS beat and in-line revenue support growth trajectory.
Advances: Launch Intelligent Eyewear product line
Intelligent Eyewear aligns with product launch objectives.
Advances: Launch Intelligent Eyewear product line
AI integration supports Intelligent Eyewear product line launch.
Threatens: Launch Intelligent Eyewear product line
Underwhelming launch may hinder Intelligent Eyewear product line.
Advances: Launch Intelligent Eyewear product line
Eyewear launch aligns with management's product objectives.
Advances: Launch Intelligent Eyewear product line
Intelligent Eyewear launch aligns with management's product objectives.
Advances: Achieve 10% to 12% revenue growth in 2026
Strong revenue growth supports 10-12% growth objective.
